Short Sellers Take Mixed Stance on Major Pharma

Health and Healthcare

Published: May 25, 2016 8:15 am

Last Updated: January 13, 2020 7:36 am

The short interest data have been released for the May 13 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.

Pfizer Inc. (NYSE: PFE) saw its short interest drop to 84.20 million shares from the previous 108.39 million. Shares of Pfizer closed Tuesday at $34.10, within a 52-week trading range of $28.25 to $36.46.

Merck & Co. Inc. (NYSE: MRK) had a slight increase in short interest to 27.87 million shares from 27.68 million in the previous period. Merck shares closed Tuesday at $55.60, in a 52-week range of $45.69 to $61.70.

ALSO READ: The 5 Most Shorted NYSE Stocks: Short Sellers Pick a New Favorite

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest increased to 26.20 million shares. The previous level was 24.61 million. The current level is the highest in the past 52 weeks. Shares of Teva closed Tuesday at $51.89, in a 52-week range of $49.51 to $72.31.

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest decrease to 17.59 million shares from the previous reading of 19.64 million. Shares closed Tuesday at $71.23, within a 52-week range of $51.82 to $73.06.

AbbVie Inc. (NYSE: ABBV) short interest increased to 28.10 million shares, compared to the previous level of 20.99 million. Shares of AbbVie closed Tuesday at $60.70, in a 52-week trading range of $45.45 to $71.60.

It’s Your Money, Your Future—Own It (sponsor)

Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.